Promising Drugs in Boehringer-Ingelheim Pipeline
Compound* | Clinical phase | Indication | Therapeutic principle | Mode of action |
---|---|---|---|---|
Olodaterol | Submitted | Chronic obstructive pulmonary Disease (COPD) | Long-acting beta-agonist | Bronchodilation |
Tiotropium | Submitted | Cystic fibrosis (CF) | Bronchodilatator | Long Acting Muscarinic Antagonist |
Afatinib | Phase III | Breast cancer | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
Afatinib | Phase III | Head and neck cancer | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
Deleobuvir (BI 207127) |
Phase III | Hepatitis C | Direct acting antiviral small molecule | Oral NS5B RNA-dependent polymerase inhibitor |
Empagliflozin | Phase III | Diabetes mellitus type II |
SGLT-2-inhibitor | Inhibition of glucose transporter-2 |
Faldaprevir (BI 201335) |
Phase III | Hepatitis C | Direct acting antiviral small molecule | Oral HCV NS3/4A protease inhibitor |
Nintedanib | Phase III | Non-small cell lung cancer (NSCLC) | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
Nintedanib | Phase III | Ovarian cancer | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
Nintedanib | Phase III | Idiopathic pulmonary fibrosis (IPF) | Anti-fibrotic kinase inhibition | Anti-fibrotic kinase inhibitor |
Tiotropium | Phase III | Asthma | Bronchodilatator | Long Acting Muscarinic Antagonist |
Volasertib | Phase III | Various cancer types | Cell-cycle kinase inhibition | PLK-1 antagonist |
* These are investigational agents; their safety and efficacy have not yet been established.
Status: April 2013
Successful Products from our Boehringer-Ingelheim Research & Development
Product name | First launch | Active ingredient | Indication |
---|---|---|---|
Gilotrif™ | 2013 | Afatinib | Non-small cell lung cancer (NSCLC) |
Trajenta® | 2011 | Linagliptin | Diabetes mellitus type II |
Pradaxa® | 2010 2008 |
Dabigatran etexilate | Stroke prevention in atrial fibrillationPrevention of venous thromboembolic events (VTE) in adults |
Spiriva® Respimat Soft Mist™ InhalerSpiriva® |
2007 2002 |
Tiotropium | COPD |
Micardis® | 1998 | Telmisartan | Essential hypertension |
Sifrol® / Mirapex® /Mirapexin® | 20061997 | Pramipexole | Restless legs syndrome (RLS) Parkinson’s disease (PD) |
Viramune® | 1996 | Nevirapine | HIV/AIDS |
Oncology Websites
No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player